Drug development and the deficit syndrome of schizophrenia

Biological Psychiatry

Volumn 38, Issue 5, 1995, Pages 277-278

  Kirkpatrick, Brian ^a   Carpenter Jr , William T ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

ANIMAL MODEL; DRUG DEVELOPMENT; EDITORIAL; HUMAN; NEGATIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA;

AFFECTIVE SYMPTOMS; ANIMAL; ANTIPSYCHOTIC AGENTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMAN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029077142     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00350-P     Document Type: Editorial

References (12)

1. Parallel organization of functionally segregated circuits linking basal ganglia and cortex
2. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
3. Differential neuropsychological impairments in deficit vs nondeficit forms of schizophrenia
4. Deficit and non-deficit forms of schizophrenia: The concept
5. Strong inference, theory testing, and the neuroanatomy of schizophrenia
6. Clozapine response varies in deficit vs non-deficit schizophrenic subjects
7. Treatment of schizophrenia A clinical and preclinical evaluation of neuroleptic drugs
8. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to resperidone
9. Psychiatric disease and the neurobiology of social behavior
10. The neural basis of the deficit syndrome of schizophrenia
11. The Schedule for the Deficit Syndrome: An instrument for research in schizophrenia
12. Neuroleptic-induced anhedonia: Recent studies